PFE
Pfizer Inc.
Cash flow statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 14.2B | 11.7B | 12.7B | 8.7B | 29.3B | 32.6B | 14.4B | 12.6B | 15.8B | 16.8B | 16.2B | 14.7B | 17.1B | 17.7B | 16.7B | 20.2B | 11.5B | 16.6B | 18.2B | 13.4B |
| 2.39B | 2.63B | 2.91B | 3.91B | 3.24B | 2.71B | 2.23B | 2.05B | 1.98B | 1.96B | 1.82B | 1.40B | 1.20B | 1.21B | 1.33B | 1.66B | 1.51B | 1.21B | 1.70B | 1.88B | |
| Free cash flow | 11.8B | 9.1B | 9.8B | 4.8B | 26.0B | 29.9B | 12.2B | 10.5B | 13.8B | 14.8B | 14.4B | 13.3B | 15.9B | 16.5B | 15.4B | 18.6B | 9.9B | 15.4B | 16.5B | 11.5B |
| Depreciation and amortization | 6.50B | 6.59B | 7.01B | 6.29B | 5.06B | 5.19B | 4.68B | 5.76B | 6.38B | 6.27B | 5.76B | 5.16B | 5.54B | 6.31B | 7.39B | 8.70B | 8.40B | 4.76B | 5.09B | 5.20B |
| Stock-based compensation | 1.11B | 0.80B | 0.88B | 0.53B | 0.87B | 1.18B | 0.76B | 0.69B | 0.92B | 0.84B | 0.69B | 0.67B | 0.59B | 0.52B | 0.48B | 0.42B | 0.41B | 0.35B | 0.38B | 0.44B |
| Buybacks | — | — | 0 | 0 | 2.0B | 0 | 0 | 8.9B | 12.2B | 5.0B | 5.0B | 6.2B | 5.0B | 16.3B | 8.2B | 9.0B | 1.0B | 0 | 500M | 10.0B |
| Dividends per share | 1.72 | 1.72 | 1.69 | 1.65 | 1.61 | 1.57 | 1.53 | 1.46 | 1.38 | 1.28 | 1.20 | 1.12 | 1.04 | 0.96 | 0.88 | 0.80 | 0.72 | — | — | — |
| Free cash flow margin | 18.5% | 14.5% | 15.5% | 8.0% | 25.7% | 36.7% | 29.2% | 25.8% | 33.9% | 28.3% | 27.2% | — | — | 31.9% | 28.2% | 30.4% | 15.3% | 31.2% | 34.2% | 23.7% |